ABBV financials
AbbVie Inc. · end-of-day data as of Oct 16, 2026
AbbVie Inc.
$285.42+10.7%
Buy · 30 analystsPT $281.54 -1.4%
ABBV reported revenue of $16.99B for the quarter ended Jun 30, 2026 (Q2 FY2026), up 10.2% from a year earlier. It posted diluted EPS of $2.04, free cash flow of $3.11B and a net margin of 21.3%.
Valuation
- P/E80.4x
- P/E vs own-28.2%
- P/E vs sector+185.6%
- FCF yield+3.6%
- Market cap$504B
Quarterly results
Q2 FY2026: Revenue +10.2% year over year, free cash flow 18.3% of revenue, operating margin 37.9%.
RevenueFree cash flow
| Q2 FY2026 | Jun 30, 2026 | $16.99B | 2.04 | $3.11B | 74.7% | 37.9% | 21.3% |
| Q1 FY2026 | Mar 31, 2026 | $15B | 0.39 | $3.56B | 71.9% | 31.6% | 4.7% |
| Q4 FY2025 | Dec 31, 2025 | $16.62B | 1.02 | $4.89B | 72.6% | 35.0% | 10.9% |
| Q3 FY2025 | Sep 30, 2025 | $15.78B | 0.10 | $6.64B | 66.4% | 12.1% | 1.2% |
| Q2 FY2025 | Jun 30, 2025 | $15.42B | 0.53 | $4.88B | 71.8% | 31.7% | 6.1% |
| Q1 FY2025 | Mar 31, 2025 | $13.34B | 0.72 | $1.4B | 70.0% | 28.0% | 9.6% |
| Q4 FY2024 | Dec 31, 2024 | $15.1B | -0.02 | $6.76B | 70.9% | -9.9% | -0.1% |
| Q3 FY2024 | Sep 30, 2024 | $14.46B | 0.88 | $5.2B | 70.9% | 26.5% | 10.8% |
| Q2 FY2024 | Jun 30, 2024 | $14.46B | 0.77 | $2.03B | 70.9% | 27.6% | 9.5% |
| Q1 FY2024 | Mar 31, 2024 | $12.31B | 0.77 | $3.85B | 66.7% | 22.7% | 11.1% |
| Q4 FY2023 | Dec 31, 2023 | $14.3B | 0.46 | $4.55B | 60.1% | 22.3% | 5.7% |
| Q3 FY2023 | Sep 30, 2023 | $13.93B | 1.00 | $7.36B | 53.4% | 16.4% | 12.8% |